Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of ...

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for ...

Crispr Therapeutics is a clinical-stage gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly ...

Sickle Cell Anemia Individuals with sickle cell anemia are grateful for gene editing innovations because they say CRISPR is life-changing. Humans have genes that make hemoglobin. When they have ...

Editas Medicine EDIT incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus ...

Nobel Prize winner and UC Berkeley professor Jennifer Doudna presented developments on her gene research at a UC Santa Barbara Arts & Lectures event on Oct. 22.

Scientists uncover how a single gene drives honey bee cooperation, revealing the genetic basis behind hive behavior and social unity.

Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the third quarter 2024 and ...

Introduction to HEK 293 Cells HEK 293 cells, also known as Human Embryonic Kidney 293 cells, have become a crucial tool in ...

Cancer continues to be a formidable challenge globally, with traditional drug discovery methods focusing on cytotoxic agents and targeted therapies altering the landscape of cancer prognosis and ...